BDX vs PPCB · P/E 34, rev $21.84B vs P/E 0.0, $3.9M cap
Becton Dickinson and Company (BDX) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
PPCB does not have a complete income-statement cache yet.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the BDX and PPCB stock pages for the full models.
Not investment advice.